SCY-078, a novel IV/oral triterpenoid anti-fungal treatment in development for vulvovaginal candidiasis and other severe invasive fungal infections, is not embryo/feto-toxic

Administration of azoles, like fluconazole, in the treatment of difficult-to-treat fungal infections in pregnant women have been correlated with observations of congenital abnormalities in infants exposed in utero. Here we present developmental and reproductive toxicity data for a novel triterpenoid glucan synthase inhibitor, SCY-078, with proven anti-fungal activity against Candida, Aspergillus and Pneumocystis spp. currently in clinical development for the treatment of Vulvovaginal Candidiasis (VVC) and other severe invasive fungal infections.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: IDSOG Abstract Source Type: research